

FAST, ACCURATE LIQUID BIOPSY DETECTION OF BRAIN DISEASE

A best-in-class commercial stage immunoassay with potential to gain traction as an early and accurate diagnostic tool for the assessment and classification of brain trauma and neurodegeneration.

www.umandiagnosics.com

SALSS CONTACT

Niklas Norgren
CEO

niklas.norgren@umandiagnosics.se
+46 90 777 880

UmanDiagnostics AB
Tvistevägen 48C
907 36 Umeå
Sweden

SALSS RISING STAR | 2018



UmanDiagnostics

Rapid detection of brain disease

Uman Diagnostics AB | Private Company

Uman Diagnostics, founded in 2006, is an innovative in vitro diagnostics company focusing on early accurate diagnosis of traumatic and degenerative diseases of the brain. The Company's immunoassay is on market with global sales, and is ripe for expansion in partnership with a major diagnostics or pharma player.

OUR PRODUCTS & SERVICES

Early and accurate diagnosis via liquid biopsy from cerebrospinal fluid (CSF) and blood is a holy grail to manage the growing challenges of neurodegenerative disorders and traumatic brain injuries, ranked third in global disease burden by WHO.

Uman Diagnostics' commercial NF-light® ELISA allows fast quantification of the level of neurofilament light (NFL) in CSF, a potent biomarker. NFL which originates as cytoskeletal proteins in neuronal cells, has been shown to be associated with diagnosis of Alzheimer's; to be a strong predictor of disease activity in multiple sclerosis; to differentiate between Parkinson's disease and atypical Parkinson's disease; and predict outcome in traumatic brain injuries.

NF-light® is regarded as the "gold standard" and used in clinical routine in a number of the European Union member states. NF-light® reagents are also sold as stand-alone, *Research Use Only*, products. The US is currently the largest market, followed by the EU, where sales are handled by IBL International, excluding the Nordic countries. Manufacturing takes place in Sweden.

WHAT MAKES US UNIQUE

NF-light® ELISA is extensively validated, with almost 200 scientific papers published using our test or specific reagents. Uman Diagnostics aims to extend its lead as the fastest, lowest cost "gold standard" diagnostic assay for TBI and CNS disorders, reducing reliance on imaging techniques and their associated high radiation dosage.

Increased sensitivity now enables a shift from CSF to a blood-based assay, which could increase the potential for NF-light® to be used as a routine screening and diagnostic tool in an out-patient setting, requiring only a minimally invasive blood draw.

WHY YOU SHOULD MEET US

Uman is looking both to increase its customer base and identify a major partner with the global reach and interest to scale up the success that has been achieved so far in establishing NF-light® in clinical and research use.

KEY TEAM

Niklas Norgren PhD

• CEO

Bo Hammarström

• Board Member

Torgny Stigbrand

• Chairman & Scientific
Advisor

SWEDISH
AMERICAN
LIFE SCIENCE
SUMMIT
2018